Literature DB >> 21768528

Implications of new hypertension guidelines in the United States.

Monica L Bertoia1, Molly E Waring, Priya S Gupta, Mary B Roberts, Charles B Eaton.   

Abstract

The American Heart Association Task Force released a scientific statement in 2007 for the treatment of hypertension in the prevention of coronary artery disease (CAD). These guidelines recommend more aggressive control of blood pressure (BP) among those at high risk for CAD: individuals with diabetes mellitus, chronic kidney disease, cardiovascular disease, congestive heart failure, or a 10-year Framingham risk score ≥10%. These individuals are advised to maintain a BP <130/80 mm Hg. We estimated the burden of uncontrolled BP among those at an increased risk of CAD using the updated task force guidelines. We used a cross-sectional analysis of National Health and Nutrition Examination Survey 2005-2008 participants. Participants were 24 989 adults aged 18 to 85 years. Using the old definition of hypertension (>140/90 mm Hg), 98 million (21%) Americans have hypertension. Using the updated guidelines, an additional 52 million (11%) American adults now have elevated BP requiring treatment, for a total of 150 million adults (32%). Adults with diabetes mellitus have the greatest population burden of uncontrolled BP (50.6 million), followed by adults with chronic kidney disease (43.7 million) and cardiovascular disease (43.3 million). Although individuals at a higher risk for CAD are more likely to be aware of their hypertension and to be taking antihypertension medication, they are less likely to have their BP under control. Additional efforts are needed in the treatment of elevated BP, especially among individuals with an increased risk of CAD.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21768528     DOI: 10.1161/HYPERTENSIONAHA.111.175463

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  10 in total

1.  [Systolic pressure in wound scarring].

Authors:  J M Pereira De Godoy
Journal:  G Chir       Date:  2014 Nov-Dec

2.  Prevalence of undiagnosed and inadequately treated type 2 diabetes mellitus, hypertension, and dyslipidemia in morbidly obese patients who present for bariatric surgery.

Authors:  Rouzbeh Mostaedi; Denise E Lackey; Sean H Adams; Stephen A Dada; Zahid A Hoda; Mohamed R Ali
Journal:  Obes Surg       Date:  2014-06       Impact factor: 4.129

3.  Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients.

Authors:  Augustine N Odili; Birinus Ezeala-Adikaibe; Mouhamadou B Ndiaye; Benedict C Anisiuba; Marius M Kamdem; Chinwuba K Ijoma; Joseph Kaptue; Hilaire J Boombhi; Philip M Kolo; Elvis N Shu; Lutgarde Thijs; Jan A Staessen; Babatunde A Omotoso; Samuel Kingue; Serigne A Ba; Daniel Lemogoum; Jean-René M'Buyamba-Kabangu; Ifeoma I Ulasi
Journal:  Trials       Date:  2012-05-17       Impact factor: 2.279

4.  The 3'-UTR of the adiponectin Q gene harbours susceptibility loci for atherosclerosis and its metabolic risk traits.

Authors:  Nzioka Muiya; Mohammed Al-Najai; Asma I Tahir; Samar Elhawari; Daisy Gueco; Editha Andres; Nejat Mazhar; Nada Altassan; Brian F Meyer; Maie Alshahid; Nduna Dzimiri
Journal:  BMC Med Genet       Date:  2013-12-13       Impact factor: 2.103

5.  Best practices for scientific computing.

Authors:  Greg Wilson; D A Aruliah; C Titus Brown; Neil P Chue Hong; Matt Davis; Richard T Guy; Steven H D Haddock; Kathryn D Huff; Ian M Mitchell; Mark D Plumbley; Ben Waugh; Ethan P White; Paul Wilson
Journal:  PLoS Biol       Date:  2014-01-07       Impact factor: 8.029

6.  Longitudinal association of dairy consumption with the changes in blood pressure and the risk of incident hypertension: the Framingham Heart Study.

Authors:  Huifen Wang; Caroline S Fox; Lisa M Troy; Nicola M Mckeown; Paul F Jacques
Journal:  Br J Nutr       Date:  2015-09-23       Impact factor: 3.718

7.  Proteomic response to acupuncture treatment in spontaneously hypertensive rats.

Authors:  Xinsheng Lai; Jiayou Wang; Neel R Nabar; Sanqiang Pan; Chunzhi Tang; Yong Huang; Mufeng Hao; Zhonghua Yang; Chunmei Ma; Jin Zhang; Helen Chew; Zhenquan He; Junjun Yang; Baogui Su; Jian Zhang; Jun Liang; Kevin B Sneed; Shu-Feng Zhou
Journal:  PLoS One       Date:  2012-09-12       Impact factor: 3.240

8.  Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.

Authors:  Dean J Kereiakes; Steven G Chrysant; Joseph L Izzo; Thomas Littlejohn; Michael Melino; James Lee; Victor Fernandez; Reinilde Heyrman
Journal:  Cardiovasc Diabetol       Date:  2012-10-30       Impact factor: 9.951

9.  Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.

Authors:  Emma Robinson; Roslyn S Cassidy; Mitchel Tate; Youyou Zhao; Samuel Lockhart; Danielle Calderwood; Rachel Church; Mary K McGahon; Derek P Brazil; Barbara J McDermott; Brian D Green; David J Grieve
Journal:  Basic Res Cardiol       Date:  2015-03-01       Impact factor: 17.165

10.  Medication Adherence and Blood Pressure Control Among Hypertensive Patients With Coexisting Long-Term Conditions in Primary Care Settings: A Cross-Sectional Analysis.

Authors:  Yu Ting Li; Harry H X Wang; Kirin Q L Liu; Gabrielle K Y Lee; Wai Man Chan; Sian M Griffiths; Ruo Ling Chen
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.